Blueprint Medicines (BPMC) Misses Q2 EPS by 44c

Blueprint Medicines (NASDAQ: BPMC) reported Q2 EPS of ($2.68), $0.44 worse than the analyst estimate of ($2.24). Revenue for the quarter came in at $36.5 million versus the consensus estimate of $36.85 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Solstice acquiring Element Solutions in $14.5B cash and stock deal
• S&P Global releases recast financials after Mobility spin-off
• Nephros added to Russell Microcap Index after 2026 reconstitution